[Patient-related independent clinical risk factors for early complications following interventional pulmonology procedures].

Related Articles

[Patient-related independent clinical risk factors for early complications following interventional pulmonology procedures].

Beijing Da Xue Xue Bao. 2016 Dec 18;48(6):1006-1011

Authors: Huang JJ, Zhang H, Zhang W, Wang X, Gong YH, Wang GF

Abstract
OBJECTIVE: To investigate the early complication rate and identify patient-related independent clinical risk factors for early complications in patients following interventional pulmonology procedures.
METHODS: In the period from December 2014 to December 2015, sufficient data of Peking University First Hospital Respiratory and Critical Care Medicine Department for analysis were identified in 218 subjects. Interventional pulmonology procedures were performed in all the patients. Early complications after the procedures were defined as newly respiratory failure, arrhythmia requiring treatment, severe hemoptysis, pneumothorax, pneumomediastinum, pulmonary edema, tracheoesophageal fistulae, bronchopleural fistulae, acute coronary syndrome, acute cerebrovascular accident, and death. Patient-related clinical risk factors were defined as coronary atherosclerotic heart disease, cerebral infarction, diabetes mellitus, cirrhosis, chronic kidney disease, arrhythmia, asthma, chronic obstructive pulmonary disease, hypertension, and previous interventional pulmonology treatment. The patient-related independent clinical risk factors which had close relations to the occurrence of early complications were analyzed by multivariate statistical analysis with Logistic regression.
RESULTS: There were 56.4% male and 43.6% female subjects in this study. There were 10.6% current smokers, 26.6% former smokers, and 62.8% non-smokers. The overall early complication rate was 8.3%. In all the subjects groups, the patient-related independent clinical risk factors for the early complication rate were coronary atherosclerotic heart disease (B=1.545, P=0.006, OR=4.686, 95% CI 1.568-14.006), chronic obstructive pulmonary disease (B=1.037, P=0.049, OR=2.820, 95% CI 1.675-11.790), and current smoking status (B=1.412, P=0.032, OR=4.139, 95% CI 1.134-15.109); for the newly respiratory failure rates were coronary atherosclerotic heart disease (B=2.207, P=0.004, OR=9.087, 95% CI 2.028-40.714), chronic obstructive pulmonary disease (B=1.646, P=0.048, OR=5.188, 95% CI 1.783-34.375), and lesions involving three central airways (B=1.899, P=0.032, OR=6.680, 95% CI 1.182-37.740). In the malignant group, the patient-related independent clinical risk factor for the early complication rate was current smoking status (B=2.953, P=0.006, OR=19.161, 95% CI 2.360-155.572). In the benign group, the patient-related independent clinical risk factor for the early complication rate was only coronary atherosclerotic heart disease (B=1.976, P=0.022, OR=7.214, 95% CI 1.324-39.298).
CONCLUSION: Closer monitoring of patients with identified clinical risk factors is advisable prior and immediately after interventional pulmonology procedures. In order to avoid or minimize early complications, special attention should be directed toward patients who are current smokers, or patients with lesions involving three central airways, or with coronary atherosclerotic heart disease or chronic obstructive pulmonary disease.

PMID: 27987505 [PubMed – in process]

View full post on pubmed: asthma

Concomitant MAZE procedure during cardiac surgical procedures, is there any survival advantage in conversion to sinus rhythm?

Related Articles

Concomitant MAZE procedure during cardiac surgical procedures, is there any survival advantage in conversion to sinus rhythm?

Minerva Cardioangiol. 2014 Oct 30;

Authors: Neragi-Miandoab S, Skripochnik E, Michler RE, Friedman P, D’alessandro DA

Abstract
BACKGROUND: The MAZE procedure, or concomitant intraoperative ablation, is an effective technique to restore long–term sinus rhythm (SR). The survival benefit of conversion to SR has been questioned recently.
METHODS AND RESULTS: We retrospectively evaluated the conversion rate to SR and its correlation with long–term survival in 209 patients with chronic AF, who had a MAZE procedure during cardiac surgical procedures between the years 2006 and 2011 at our institution. The mean age was 67.2 ± 12.0 years and 52.2% were female (n=109). Perioperative mortality was 5.74% (n=12). In univariate analysis, significant risk factors for perioperative mortality were age (p=0.0033), duration of perfusion time (p=0.0093), elevated creatinine (?1.6 mg/dL, p=.02), and cross clamp time (p=0.016). In multivariate analysis age (HR 2.97) and duration of perfusion time (HR 1.48) were the only independent predictors of perioperative mortality. The overall one and five–year survival rates were 88%±2.2%, and 76%±3.3%, respectively. The one and five–year survival rates for patients who converted and were in sinus rhythm (SR) upon discharge (n=154) were 88%±2.6% and 80%±3.5%, respectively. While the one and five–year survival rates for patients who were still in AF upon discharge (n=55) were 94%±3% and 82%±6.6%, respectively, this survival difference was not statistically significant (p=0.24). Significant risk factors for long–term mortality included DM (p=0.023), preoperative MI (p=0.043), preoperative renal insufficiency (creatinine, ?1.6 mg/dL, p=0.02) and asthma/COPD (p=0.040). In multivariate analysis, age (HR 1.048) and preoperative MI (HR 1.948) were the only independent predictors of long–term mortality.
CONCLUSION: The surgical MAZE procedure has a high conversion rate, however, our data did not show improved survival in patients who converted to SR prior to discharge.

PMID: 25358018 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

Registry of Bronchial Thermoplasty (BT) Procedures EMEA BT Registry.

Condition:   Asthma
Intervention:   Device: Alair System (Bronchial Thermoplasty)
Sponsors:   Boston Scientific Corporation;   Steering Committee member: Robert Niven, MD;   Steering Committee member: Alfons Torrego, MD;   Steering Committee member: Felix Herth, MD;   Steering Committee member: Narinder Shargill, PhD
Recruiting – verified January 2014

View full post on ClinicalTrials.gov: asthma | received in the last 14 days